Abstract
Commentary
This background provides a basis for a reexamination of the situation among babies born almost 30 years later. The NCPP data provided a perspective that informed many of the ensuing attempts to understand and characterize neonatal seizures more fully, in the hope that better interventions would lead to better outcomes. The Ronen et al. study reviewed here suggests that these hopes have not been realized. Although neonatal seizures were less frequent (0.26%) than in the initial (NCPP) study, the finding may simply reflect more rigid “entry” criteria and fewer hypocalcemic seizures, as these seizures are currently prevented and managed far better. Death has been somewhat averted; however, there does not appear to be an increase in normal outcomes, with epilepsy occurring in 34% of all births and 48% of premature infants. Epilepsy that follows neonatal seizures may be particularly problematic, as the risk of infantile spasms in this group is 100 times the normal population. A question that always arises with studies from different eras is whether the comparison is actually among apples and oranges. The populations differed significantly, and certainly more premature babies are kept alive today than were 40 years ago.
Of note in the Ronen et al. paper is that the number of seizures did not correlate with outcome, but the type of seizures did. Premature babies with myoclonic seizures had a particularly high mortality. Continuing controversy exists with respect to whether particular seizure types correlate with poorer outcome, and if so, why? Is it because, as Lombroso suggests (3), that these infants have experienced more severe CNS insults— reflected by the inability to detect EEG changes embedded in very abnormal background activity? The severity of the underlying disorder (e.g., encephalopathy) as well as the period of development in which it occurs influences outcome. Brunquell et al. similarly reported that clinical semiology was predictive of outcome and asserted that unique pathophysiologic processes underlie the different seizure types (4). The authors speculated that understanding these relationships might well lead to improved interventions.
In the past few decades, neuroscience has continued to probe the unique aspects of neonatal seizures. Recognizing the unique role of GABAA receptors in neonates, Dzhala and colleagues (reviewed in the Basic Science section of this issue) have demonstrated enhanced phenobarbital efficacy with the use of bumetanide that blocks the NKCC1 transporter and alters Cl= flux (5). Similarly, Sankar and Rho emphasize the detrimental effects of prolonged seizures on brain plasticity on the developing brain (6). Finally, Lombroso questions whether neonatal seizures “plant the roots for epileptogenesis and cause long-term deficits” (7). Lombroso concludes that there is no convincing evidence that the seizures themselves produce epileptogenesis, but rather that they are the marker of the underlying problem. This assertion does not mean that the outcome of the underlying etiology (often hypoxia-ischemia) is immutable.
Although the paper by Sun and colleagues, reviewed here, does not deal with neonatal seizures, it provides further information about the vulnerability of the newborn and examines some of the factors associated with developing epilepsy. In this population-based study in which children were followed for up to 24 years, a crude incidence rate of epilepsy of 92.6 in 100,000 is provided. The incidence rate of epilepsy was associated with decreasing gestational age and intrauterine growth restriction. Thus, it may be of value to examine again the reasons for premature delivery—reassessing the causal roles of the intrauterine environment and fetal health in the development of neonatal seizures. The immature brain of a premature child is disadvantaged and susceptible to further insults, making it more difficult to successfully achieve developmental processes critical to normal outcome. A somewhat similar, recent population-based study from Nova Scotia again found neonatal seizures to be a most important risk factor for development of epilepsy and went so far as to suggest that: “if no infants were born small for gestational age, then 7.4% of epilepsy would be prevented (assuming causality)” (8). There is always a caveat!
Researchers and clinicians have come a long way in helping vulnerable newborns survive; however, many challenges lay ahead. The possibilities of strategies (e.g., hypothermia, novel anticonvulsants, or neuroprotective agents) to treat neonates with seizures are alluring (9), but we have a long way to go.
